Compare CNNE & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNNE | AQST |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 497.5M | 504.0M |
| IPO Year | 2017 | 2007 |
| Metric | CNNE | AQST |
|---|---|---|
| Price | $13.52 | $4.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $20.25 | $9.00 |
| AVG Volume (30 Days) | 485.7K | ★ 1.1M |
| Earning Date | 05-11-2026 | 05-01-2026 |
| Dividend Yield | ★ 4.47% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $499,700,000.00 | $67,430,000.00 |
| Revenue This Year | N/A | $10.08 |
| Revenue Next Year | N/A | $49.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.37 | 0.77 |
| 52 Week Low | $10.46 | $2.22 |
| 52 Week High | $21.96 | $7.55 |
| Indicator | CNNE | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 63.28 | 55.89 |
| Support Level | $11.54 | $3.70 |
| Resistance Level | $16.41 | $4.35 |
| Average True Range (ATR) | 0.36 | 0.14 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 67.96 | 55.56 |
Cannae Holdings Inc is an investment holding company that acquires and actively manages equity interests in operating businesses across various industries. The Company focuses on long-term ownership and seeks to create value by supporting the growth and operations of its portfolio companies through management expertise and strategic oversight. The Company operates through four reportable segments: Restaurant Group, which includes the operations of O'Charleys and 99 Restaurants; Alight, which represents its ownership interest in a technology-enabled human capital and employee benefits solutions provider; Black Knight Football Club (BKFC), which holds interests in professional football clubs; and JANA, which represents its investment in an investment management firm.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.